English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Dipeptidyl peptidase-4 inhibitors (DPP-4) is a new class of hypoglycemic drugs developed based on the knowledge of incretin physiology acquired in the 21st century. Currently, five members of this group are in use three of which are available on the Russian market. The hypoglycemic effect of dipeptidyl peptidase-4 inhibitors is due to reduction of fasting and postprandial hyperglycemia without a rise in the body weight and acceptable profile of side effects. Dipeptidyl peptidase-4 inhibitors differ in terms of pharmacodynamics and pharmacokinetics which implies different indications and duration of their use in different groups of patients as well as different character of their drug interaction. This paper compares three dipeptidyl peptidase-4 inhibitors, viz. vildagliptin, sitagliptin, and saxagliptin.

Dipeptidyl peptidase-4 inhibitors: Comparative analysis of members of the group